Axsome Therapeutics - AXSM Stock Forecast, Price & News

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Axsome Therapeutics Trading Up 2.1 %

NASDAQ:AXSM traded up $0.95 on Friday, hitting $46.27. 603,193 shares of the stock were exchanged, compared to its average volume of 839,697. The company has a debt-to-equity ratio of 6.15, a quick ratio of 3.54 and a current ratio of 2.44. The company's 50-day moving average price is $36.27 and its 200 day moving average price is $33.69. Axsome Therapeutics has a 52 week low of $19.38 and a 52 week high of $48.82.

Axsome Therapeutics (NASDAQ:AXSM - Get Rating) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($1.06) EPS for the quarter, beating analysts' consensus estimates of ($1.19) by $0.13. During the same period in the prior year, the firm earned ($0.86) earnings per share. On average, equities research analysts forecast that Axsome Therapeutics will post -4.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on AXSM shares. Morgan Stanley lifted their price target on Axsome Therapeutics from $54.00 to $55.00 and gave the company an "equal weight" rating in a report on Wednesday. Cowen lifted their price target on Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a report on Wednesday, June 29th. Cantor Fitzgerald cut their price target on Axsome Therapeutics from $64.00 to $54.00 in a report on Wednesday. Cowen lifted their price target on Axsome Therapeutics from $120.00 to $130.00 and gave the company an "outperform" rating in a report on Wednesday, June 29th. Finally, Mizuho cut their price target on Axsome Therapeutics from $51.00 to $49.00 in a report on Tuesday, May 3rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Axsome Therapeutics has an average rating of "Moderate Buy" and an average target price of $90.63.